Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,831 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06948448RecruitingPhase 2
New treatment for advanced colorectal cancer with PD-L1 biomarker
This trial tests a new drug (ONO-4578) combined with standard chemotherapy and immunotherapy for people with advanced colorectal cancer that has not been treated before and has a specific marker called PD-L1. The goal is to see if this combination works better than the usual treatment.
Phoenix, ArizonaAges 18 years+ - NCT07225270RecruitingPhase 3
Study of Rina-S plus care for ovarian cancer maintenance
This trial tests whether adding Rina-S to standard maintenance therapy helps prevent cancer from returning in people with recurrent platinum-sensitive ovarian cancer who have responded to second-line platinum-based chemotherapy.
Miami, FloridaAges 18 years+ - NCT06478719RecruitingPhase 1/Phase 2
FB-1603 plus TACE for liver cancer patients
This trial tests a new medicine (FB-1603) given along with standard TACE procedure for people with liver cancer. It aims to see if the combination is safe and works better than TACE alone.
Taipei, TaiwanAges 18–85 - NCT07704554Recruiting
Dural puncture epidural for labor pain relief
This study compares a modified epidural technique (dural puncture epidural) to the standard method for managing labor pain. It aims to see if the new approach is safer or works better for women in labor.
Columbus, OhioAges 18 years+ - NCT07602777RecruitingPhase 1/Phase 2
Testing Risvutatug Rezetecan for Advanced Bone and Soft Tissue Sarcomas
This study tests a new cancer drug called risvutatug rezetecan for people with advanced sarcomas (bone or soft tissue cancers) that have stopped responding to prior treatments. The drug works by delivering a cancer-killing agent directly to tumor cells.
Toronto, OntarioAges Any age - NCT07453888RecruitingPhase 3
Nose spray for sudden vision loss from optic nerve damage
This trial tests a nose spray medication (cenegermin) for people who recently lost vision due to a specific type of optic nerve damage (NAION). The goal is to see if it can help restore sight when started within two weeks of vision loss.
Los Angeles, CaliforniaAges 50–80 - NCT07482176RecruitingPhase 3
Gene therapy trial for wet age-related macular degeneration
This trial tests a one-time gene therapy injection (IXO-vec) for people with wet age-related macular degeneration (nAMD). It aims to reduce the need for frequent eye injections by helping the eye make its own medicine to block the growth of harmful blood vessels.
Mesa, ArizonaAges 50 years+ - NCT07010497RecruitingPhase 2
Study of a three-drug combo for advanced liver cancer
This trial tests a new combination of three drugs (Irpagratinib, Atezolizumab, and Bevacizumab) for people with advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and effective.
SeoulAges 19 years+ - NCT07104604RecruitingPhase 2
New combo before surgery for low rectal cancer
This trial tests a new combination of treatments (radiation, immunotherapy, and two chemotherapy drugs) given before surgery for people with a specific type of locally advanced rectal cancer that is close to the anus. The goal is to see if this approach is safe and effective.
Shantou, GuangdongAges 18–75 - NCT07229547RecruitingPhase 3
Onradivir for teens with flu A
This study tests an experimental antiviral pill called Onradivir for teenagers (ages 12 to 17) with uncomplicated influenza A. It aims to see if the drug can safely shorten flu symptoms and help you recover faster.
Shanghai, Shanghai MunicipalityAges 12–17 - NCT07185009RecruitingPhase 3
Testing duvakitug for long-term ulcerative colitis control
This study tests the long-term safety and effectiveness of an experimental drug called duvakitug in people with moderate to severe ulcerative colitis. It is for those who have already responded well to treatment in a previous study and need ongoing care.
Tucson, ArizonaAges 16–80 - NCT03067051RecruitingPhase 1/Phase 2
Test of a prostate cancer light-activated treatment device
This study tests the safety and early effectiveness of the SpectraCure P18 system, which uses light-activated medicine to treat prostate cancer that has come back locally after radiation. It may help some people avoid or delay more invasive treatment, while researchers carefully watch side effects.
New York, New YorkAges 18 years+ - NCT03094429RecruitingPhase 2/Phase 3
Testing NaBen add-on to clozapine for tough schizophrenia symptoms
This trial tests whether adding NaBen (a supplement-like medicine) to clozapine can improve “residual” symptoms in adults with difficult-to-treat schizophrenia. The study also checks safety and the best dose, using a placebo (inactive pill) for comparison.
Pasadena, CaliforniaAges 18–55 - NCT03108196Recruiting
Tested neobladder type after bladder cancer surgery
This trial compares two ways surgeons rebuild a new bladder using either sigmoid colon tissue or ileum (small intestine) tissue. It aims to see which option is safer and works better for people having bladder cancer surgery.
Guangzhou, GuangdongAges 18–100 - NCT03127267RecruitingPhase 3
Test of masitinib versus placebo for ALS
This Phase 3 study tests whether masitinib works better than an inactive pill (placebo) to slow ALS progression and keep it safe. It is meant for people recently diagnosed with ALS who meet specific breathing and function score requirements.
Birmingham, AlabamaAges 18–81 - NCT03424850RecruitingPhase 1/Phase 2
Tested different radiation doses for early prostate cancer
This trial studies how safe and effective different high-dose radiation levels are for prostate cancer placed directly in the prostate (HDR brachytherapy). It may help by finding a dose that controls the cancer while keeping side effects acceptable.
St Louis, MissouriAges 18 years+ - NCT03459534RecruitingPhase 3
Radotinib for CML patients after prior TKI failure
This trial tests radotinib (a targeted pill) in people with chronic-phase Philadelphia chromosome–positive CML whose previous TKIs stopped working or could not be tolerated. It aims to improve control of the leukemia while checking safety.
BarnaulAges 18 years+ - NCT03521648Recruiting
BPH treatment safety and effectiveness data collection
This trial collects information from people being treated for enlarged prostate (BPH) and related urinary symptoms to evaluate how well treatments work and how safe they are. It may help improve future care by better tracking real-world outcomes.
Sankt Gallen, Canton of St. GallenAges 18 years+ - NCT03546309Recruiting
Testing RIC to help children with moyamoya after surgery
This trial studies whether a treatment called RIC (remote ischemic conditioning) is safe and helpful for children with moyamoya disease who undergo revascularization surgery. It aims to improve outcomes after surgery and reduce risk, while carefully tracking safety.
Beijing, Beijing MunicipalityAges Up to 18 years - NCT03579836RecruitingPhase 1/Phase 2
Test BEY1107 plus gemcitabine for pancreatic cancer
This early study tests whether BEY1107 given alone or with gemcitabine can be used safely and may help shrink pancreatic cancer tumors. It mainly looks at safety, side effects, and signs of effectiveness in people with pancreatic ductal cancer.
SeoulAges 20–80 - NCT03671044RecruitingPhase 3
Testing a nano-form of docetaxel for triple-negative breast cancer
This Phase 3 study tests whether a special form of docetaxel (a chemotherapy drug) works better and is safe for people with triple-negative breast cancer that has spread or grown locally. You may be eligible if your cancer is triple-negative and you have measurable disease that can be tracked on scans, along with adequate organ and heart function.
Columbus, GeorgiaAges 18–65 - NCT03755193RecruitingPhase 2
Testing another osteoporosis medicine after 2 years of denosumab
This study looks at how well and how safely another osteoporosis medicine works for people who have already taken denosumab for 2 years. It may help find the best next step to strengthen bones and lower fracture risk after denosumab.
Matsumoto, NaganoAges 20–120 - NCT03769129Recruiting
Pembrolizumab plus lung ablation for advanced lung cancer
This trial tests whether combining pembrolizumab (an immune treatment) with a lung ablation procedure can be safer and more effective for advanced non-small cell lung cancer after standard first treatment fails or the cancer comes back. It may help shrink tumors and improve control of the disease.
Guangzhou, GuangdongAges 18 years+ - NCT03767530Recruiting
Warm or heat devices for eyelid oil gland blockage
This study tests heated devices to see if they improve dry eye caused by blocked meibomian (eyelid oil) glands. It may help if warm compresses and gentle eyelid massage didn’t work for you.
Monterrey, Nuevo LeónAges 18 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,831 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.